Michael Millward

Health Net — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index6.9kcitations77works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(40), Cutaneous Melanoma Detection and Management(17), Lung Cancer Treatments and Mutations(14), Computational Drug Discovery Methods(12), Colorectal Cancer Treatments and Studies(10)

Publications77 total

The effect of dietitian universal nutrition assessment and malnutrition documentation on patient nutritional care and revenue in an acute care hospital
Australian Health Review·2025
1108P Impact of quantitative imaging of all disease on the prognostic value of 18F-FDG PET/CT in patients treated with immunotherapy for metastatic melanoma
Annals of Oncology·2024
1155P Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Annals of Oncology·2023Open Access
Supplementary Table 2 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Suppementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Data from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Table 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Table 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Figure 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Figure 2 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Figure 2 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Figure 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Data from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Suppementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Table 2 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
2023Open Access
1358P Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor
Annals of Oncology·2021Open Access
page 1 of 4Next →

Frequent Co-authors

Axel Hauschild(8), Lev Demidov(8), Piotr Rutkowski(8), Jean‐Jacques Grob(7), Ralf Gutzmer(7), Christian U. Blank(7), Paul B. Chapman(7), Salvador Martín‐Algarra(6), Vanna Chiarion‐Sileni(6), Patricia Haney(6), Vicki Goodman(6), Thomas Jouary(5), Wilson H. Miller(5), Bogusława Karaszewska(5), Cornelia Mauch(5), Beloo Mirakhur(5), Danny Rischin(5), Guy C. Toner(5), Elin S. Gray(5), S. Swann(4)